Low-Dose Naltrexone for Pain in Hospice Patients Not on Opioids
For hospice patients not currently on opioids with refractory pain, start naltrexone at 1.5 mg daily and titrate slowly up to a maximum of 4.5 mg daily based on individual response, as this represents the established low-dose range that acts through anti-inflammatory mechanisms rather than opioid antagonism.
Critical Safety Consideration
You must ensure the patient is completely opioid-free before initiating naltrexone. The FDA labeling is unequivocal: naltrexone will precipitate severe withdrawal in opioid-dependent patients 1. Even though your question specifies the patient is not on opioids, verify this carefully—including tramadol, which is also contraindicated. A minimum 7-10 day opioid-free interval is required for short-acting opioids 1.
Dosing Protocol
Starting Dose
- Begin at 1.5 mg daily (or even lower at 1 mg if the patient is frail)
- This is substantially lower than the FDA-approved 50 mg dose for addiction treatment 1
Titration Strategy
- Increase gradually every 1-2 weeks based on pain response
- Target range: 1.5-4.5 mg daily 2, 3, 4
- Most common effective dose in cancer pain: 3.0 mg daily 2
- The maximally effective dose is highly idiosyncratic and requires individualized titration 4
Why Low-Dose?
At doses of 1-5 mg, naltrexone operates through completely different mechanisms than its FDA-approved 50 mg dose:
- Acts as a glial modulator, inhibiting microglial activation 5, 6
- Antagonizes Toll-like receptor 4, reducing pro-inflammatory cytokines 5
- Creates transient opioid receptor blockade leading to upregulation of endogenous opioid production (rebound effect) 5, 6
Evidence in Cancer Pain
Recent data specifically in cancer patients shows promise:
- 80% response rate at first follow-up (mean 66 days) in refractory cancer pain 2
- 77% response rate maintained at second follow-up (mean 105 days) 2
- Particularly effective for therapy-related neuropathy (71% response rate) 2
- Well-tolerated with only 15% discontinuation rate, mostly due to inadequate relief rather than side effects 2
Monitoring and Adverse Effects
Common but minor side effects include:
These rarely require discontinuation. In the cancer pain case series, only one patient discontinued due to diarrhea 2.
Critical Guideline Context
Important caveat: Neither the NCCN 7 nor ASCO 8 cancer pain guidelines mention low-dose naltrexone as a recommended therapy. The NCCN explicitly states that mixed agonist-antagonists should not be used in cancer pain management 7. However, this refers to standard-dose naltrexone (50 mg) used concurrently with opioids, which would precipitate withdrawal—a completely different clinical scenario than low-dose naltrexone in opioid-naive patients.
When to Consider LDN
Low-dose naltrexone is appropriate for hospice patients when:
- Pain is refractory to other non-opioid therapies
- The patient is definitively opioid-free and will remain so
- Neuropathic or inflammatory pain components are suspected
- The patient has failed multiple conventional analgesics 3
What This Means Practically
This is off-label use with emerging but limited evidence. The 2025 cancer pain case series 2 provides the most relevant data for your specific population, showing reasonable safety and effectiveness. However, you're working outside established guidelines. Have a frank discussion with the patient/family about the experimental nature, the need for slow titration to find their individual effective dose, and the absolute contraindication to concurrent opioid use.
If pain control becomes inadequate and opioids are needed, discontinue naltrexone and wait at least 72 hours before initiating opioids to avoid blocking their analgesic effects 1.